Speaker illustration

Doctor Antonio J Vallejo-Vaz

University of Seville, Seville (Spain)

Member of:

Atherothrombotic residual risk in coronary and peripheral artery disease patients on guideline-recommended antiplatelet monotherapy: baseline preliminary results from the RESRISK study

Event: ESC Congress 2021 - The Digital Experience

Topic: Secondary Prevention

Session: Risk Factors and Prevention ePosters


The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry: analyses from over 55,000 cases and 68 countries

Event: ESC Congress 2019

Topic: Lipids

Session: Late Breaking Science in Prevention 1


Predictive factors for alirocumab dose increase in patients with hypercholesterolaemia and high cardiovascular risk: from the ODYSSEY COMBO I and II trials

Event: ESC Congress 2017

Topic: Lipids (Epidemiology and Prevention)

Session: Lipids


Primary prevention of patients with high LDL-cholesterol levels greater than 4.9 mmol/l: analysis from the WOSCOPS trial

Event: ESC Congress 2016

Topic: Primary cardiovascular prevention: interventions and outcomes

Session: Clinical Trial Update Prevention


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb